ID

43493

Beschreibung

ODM derived from http://clinicaltrials.gov/show/NCT00876733

Link

http://clinicaltrials.gov/show/NCT00876733

Stichworte

Versionen (3)
  1. 09.12.13 09.12.13 - Martin Dugas
  2. 16.04.14 16.04.14 - Julian Varghese
  3. 20.09.21 20.09.21 -
Hochgeladen am

20. September 2021

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

  • Neueste
  • Älteste
  • Beliebt
  • Neueste
    • Neueste
    • Älteste
    • Beliebt

Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility NCT00876733 HIV Infections

Deutsch Englisch

Eligibility

1 Formulare  
  1. StudyEvent: Eligibility
    1. Eligibility
Einschlusskriterien
Beschreibung

Einschlusskriterien

Alias
UMLS CUI 2011AA
CL425202
Alter mindestens 18 Jahre
Beschreibung

age at least 18 Years

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0001779
SNOMED CT 2011_0131
397669002
To construct a treatment option with Viramune (nevirapine) and antiretroviral, e.g. Combivir (fixed dose combination of Zidovudine and Lamivudine), Kivexa (fixed dose combination of Abacavir and Lamivudine) or Truvada (fixed dose combination of tenofovir and emtricitabine) in male and female adult HIV type 1 infected patients
Beschreibung

To construct a treatment option with Viramune (nevirapine) and antiretroviral, e.g. Combivir (fixed dose combination of Zidovudine and Lamivudine), Kivexa (fixed dose combination of Abacavir and Lamivudine) or Truvada (fixed dose combination of tenofovir and emtricitabine) in male and female adult HIV type 1 infected patients

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0039798
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
UMLS CUI 2011AA
C0599685
UMLS CUI 2011AA
C0717880
SNOMED CT 2011_0131
324859007
UMLS CUI 2011AA
C1567988
UMLS CUI 2011AA
C0663655
SNOMED CT 2011_0131
116084008
LOINC Version 232
MTHU013841
UMLS CUI 2011AA
C0209738
SNOMED CT 2011_0131
386897000
LOINC Version 232
MTHU013847
UMLS CUI 2011AA
C1528494
UMLS CUI 2011AA
C0384228
SNOMED CT 2011_0131
422091007
LOINC Version 232
MTHU015506
UMLS CUI 2011AA
C0909839
SNOMED CT 2011_0131
404856006
LOINC Version 232
MTHU018643
UMLS CUI 2011AA
C0086582
SNOMED CT 2011_0131
248153007
HL7 V3 2006_05
M
UMLS CUI 2011AA
C0086287
SNOMED CT 2011_0131
248152002
HL7 V3 2006_05
F
UMLS CUI 2011AA
C2363741
MedDRA 14.1
10068341
UMLS CUI 2011AA
C0011900
SNOMED CT 2011_0131
439401001
LOINC Version 232
MTHU008876
HIV type 1 infected patients, who have either not been treated previously
Beschreibung

HIV type 1 infected patients, who have either not been treated previously

Datentyp

boolean

Alias
UMLS CUI 2011AA
C2363741
MedDRA 14.1
10068341
UMLS CUI 2011AA
C1518422
UMLS CUI 2011AA
C1514463
HIV type 1 infected patients, whose previous combination treatment with protease inhibitors has failed
Beschreibung

HIV type 1 infected patients, whose previous combination treatment with protease inhibitors has failed

Datentyp

boolean

Alias
UMLS CUI 2011AA
C2363741
MedDRA 14.1
10068341
UMLS CUI 2011AA
C0205156
SNOMED CT 2011_0131
9130008
UMLS CUI 2011AA
C0556895
SNOMED CT 2011_0131
229554006
UMLS CUI 2011AA
C0033607
SNOMED CT 2011_0131
412127001
UMLS CUI 2011AA
C0231175
HIV type 1 infected patients, who have to switch their previous treatment from protease inhibitor or nucleosidaI reverse transcriptase inhibitor due to side effects or intolerability after achieving suppression of viral load below the limit of detection.
Beschreibung

HIV type 1 infected patients, who have to switch their previous treatment from protease inhibitor or nucleosidaI reverse transcriptase inhibitor due to side effects or intolerability after achieving suppression of viral load below the limit of detection.

Datentyp

boolean

Alias
UMLS CUI 2011AA
C2363741
MedDRA 14.1
10068341
UMLS CUI 2011AA
C0392747
SNOMED CT 2011_0131
243326001
UMLS CUI 2011AA
C0039798
UMLS CUI 2011AA
C0033607
SNOMED CT 2011_0131
412127001
UMLS CUI 2011AA
C1373111
UMLS CUI 2011AA
C0879626
SNOMED CT 2011_0131
281647001
MedDRA 14.1
10067484
UMLS CUI 2011AA
CL415164
HL7 V3 2006_05
OINT
UMLS CUI 2011AA
C0877596
MedDRA 14.1
10049835
Viramune (nevirapine) is indicated as part of combination therapy for the antiviral treatment of HIV-1 infected patients with advanced or progressive immunodeficiency.
Beschreibung

Viramune (nevirapine) is indicated as part of combination therapy for the antiviral treatment of HIV-1 infected patients with advanced or progressive immunodeficiency.

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
UMLS CUI 2011AA
C1444656
SNOMED CT 2011_0131
410535002
UMLS CUI 2011AA
C0556895
SNOMED CT 2011_0131
229554006
UMLS CUI 2011AA
C2363964
MedDRA 14.1
10068724
UMLS CUI 2011AA
C2363741
MedDRA 14.1
10068341
Ausschlusskriterien
Beschreibung

Ausschlusskriterien

Alias
UMLS CUI 2011AA
CL425201
Alter unter 18 Jahre
Beschreibung

Age < 18 years

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0001779
SNOMED CT 2011_0131
397669002
Pregnant female patients
Beschreibung

Pregnant female patients

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0549206
Hypersensitivity to the active substance or to any of the excipients of Viramune (nevirapine) or antiretroviral in combination with Viramune, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine).
Beschreibung

Hypersensitivity to the active substance or to any of the excipients of Viramune (nevirapine) or antiretroviral in combination with Viramune, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine).

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0020517
SNOMED CT 2011_0131
418634005
ICD-10-CM Version 2010
T78.40
UMLS CUI 2011AA
C0205177
SNOMED CT 2011_0131
55561003
UMLS CUI 2011AA
C0439861
SNOMED CT 2011_0131
105590001
UMLS CUI 2011AA
C0015237
SNOMED CT 2011_0131
360215002
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
UMLS CUI 2011AA
C0599685
UMLS CUI 2011AA
C1947911
UMLS CUI 2011AA
C0717880
SNOMED CT 2011_0131
324859007
UMLS CUI 2011AA
C1567988
UMLS CUI 2011AA
C0663655
SNOMED CT 2011_0131
116084008
LOINC Version 232
MTHU013841
UMLS CUI 2011AA
C0209738
SNOMED CT 2011_0131
386897000
LOINC Version 232
MTHU013847
UMLS CUI 2011AA
C1528494
UMLS CUI 2011AA
C0384228
SNOMED CT 2011_0131
422091007
LOINC Version 232
MTHU015506
UMLS CUI 2011AA
C0909839
SNOMED CT 2011_0131
404856006
LOINC Version 232
MTHU018643
Viramune (nevirapine) should not be readministered to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine.
Beschreibung

Viramune (nevirapine) should not be readministered to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine.

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
UMLS CUI 2011AA
C1518422
UMLS CUI 2011AA
C0376495
UMLS CUI 2011AA
C0205082
SNOMED CT 2011_0131
24484000
UMLS CUI 2011AA
C0015230
SNOMED CT 2011_0131
112625008
MedDRA 14.1
10037844
LOINC Version 232
MTHU015064
ICD-10-CM Version 2010
R21
ICD-9-CM Version 2011
782.1
UMLS CUI 2011AA
C0009812
LOINC Version 232
MTHU034799
UMLS CUI 2011AA
C0020517
SNOMED CT 2011_0131
418634005
ICD-10-CM Version 2010
T78.40
UMLS CUI 2011AA
C0019158
SNOMED CT 2011_0131
29001004
MedDRA 14.1
10019717
UMLS CUI 2011AA
CL420107
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
Viramune (nevirapine) should not be used in patients with severe hepatic impairment (Child-Pugh C) or pre-treatment GOT (Glutamic Oxaloacetic Transaminase) or GPT (Glutamic Pyruvate Transaminase) > 5 upper limit of normal until baseline GOT/GPT are stabilised < 5 upper limit of normal.
Beschreibung

Viramune (nevirapine) should not be used in patients with severe hepatic impairment (Child-Pugh C) or pre-treatment GOT (Glutamic Oxaloacetic Transaminase) or GPT (Glutamic Pyruvate Transaminase) > 5 upper limit of normal until baseline GOT/GPT are stabilised < 5 upper limit of normal.

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
UMLS CUI 2011AA
C1518422
UMLS CUI 2011AA
C1524063
SNOMED CT 2011_0131
260676000
UMLS CUI 2011AA
C0948807
MedDRA 14.1
10052254
UMLS CUI 2011AA
C4050412
UMLS CUI 2011AA
C0439106
SNOMED CT 2011_0131
257962003
UMLS CUI 2011AA
C1514463
UMLS CUI 2011AA
C0004002
SNOMED CT 2011_0131
26091008
LOINC Version 232
MTHU004883
UMLS CUI 2011AA
C0001899
SNOMED CT 2011_0131
56935002
LOINC Version 232
MTHU006766
UMLS CUI 2011AA
C1519815
Viramune (nevirapine) should not be readministered in patients who previously had GOT or GPT (Liver enzymes) > 5 ULN (upper limit of normal) during Viramune (nevirapine) therapy and had recurrence of liver function abnormalities upon readministration of Viramune (nevirapine)
Beschreibung

Viramune (nevirapine) should not be readministered in patients who previously had GOT or GPT (Liver enzymes) > 5 ULN (upper limit of normal) during Viramune (nevirapine) therapy and had recurrence of liver function abnormalities upon readministration of Viramune (nevirapine)

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
UMLS CUI 2011AA
C1518422
UMLS CUI 2011AA
C0376495
UMLS CUI 2011AA
C0205156
SNOMED CT 2011_0131
9130008
UMLS CUI 2011AA
C0004002
SNOMED CT 2011_0131
26091008
LOINC Version 232
MTHU004883
UMLS CUI 2011AA
C0001899
SNOMED CT 2011_0131
56935002
LOINC Version 232
MTHU006766
UMLS CUI 2011AA
C0857093
MedDRA 14.1
10014480
UMLS CUI 2011AA
C0347984
SNOMED CT 2011_0131
371881003
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
UMLS CUI 2011AA
C0039798
UMLS CUI 2011AA
CL429630
UMLS CUI 2011AA
C0086565
SNOMED CT 2011_0131
75183008
MedDRA 14.1
10019670
Herbal preparations containing St Johns wort (Hypericum perforatum) must not be used while taking Viramune (nevirapine) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine
Beschreibung

Herbal preparations containing St Johns wort (Hypericum perforatum) must not be used while taking Viramune (nevirapine) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0949854
UMLS CUI 2011AA
C0936242
SNOMED CT 2011_0131
51621002
UMLS CUI 2011AA
C1518422
UMLS CUI 2011AA
C1524063
SNOMED CT 2011_0131
260676000
UMLS CUI 2011AA
C0347984
SNOMED CT 2011_0131
371881003
UMLS CUI 2011AA
C1512806
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
UMLS CUI 2011AA
C0035647
SNOMED CT 2011_0131
30207005
HL7 V3 2006_05
RSK
UMLS CUI 2011AA
C0205216
SNOMED CT 2011_0131
1250004
HL7 V3 2006_05
D
UMLS CUI 2011AA
C0683150
UMLS CUI 2011AA
C0392756
SNOMED CT 2011_0131
260400001
UMLS CUI 2011AA
C1280500
SNOMED CT 2011_0131
253861007
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
The available pharmacokinetic data suggest that the concomitant use of rifampicin and Viramune (nevirapine) is not recommended.
Beschreibung

The available pharmacokinetic data suggest that the concomitant use of rifampicin and Viramune (nevirapine) is not recommended.

Datentyp

boolean

Alias
UMLS CUI 2011AA
C0031328
UMLS CUI 2011AA
C1511726
UMLS CUI 2011AA
C0038659
UMLS CUI 2011AA
C1518422
UMLS CUI 2011AA
C0034866
LOINC Version 232
MTHU036724
HL7 V3 2006_05
RMD
UMLS CUI 2011AA
CL415222
UMLS CUI 2011AA
C1524063
SNOMED CT 2011_0131
260676000
UMLS CUI 2011AA
C0035608
SNOMED CT 2011_0131
387159009
LOINC Version 232
MTHU008474
UMLS CUI 2011AA
C0132326
SNOMED CT 2011_0131
386898005
LOINC Version 232
MTHU013861
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility

1 Formulare
  1. StudyEvent: Eligibility
    1. Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Einschlusskriterien
CL425202 (UMLS CUI 2011AA)
age at least 18 Years
Item
Alter mindestens 18 Jahre
boolean
C0001779 (UMLS CUI 2011AA)
397669002 (SNOMED CT 2011_0131)
To construct a treatment option with Viramune (nevirapine) and antiretroviral, e.g. Combivir (fixed dose combination of Zidovudine and Lamivudine), Kivexa (fixed dose combination of Abacavir and Lamivudine) or Truvada (fixed dose combination of tenofovir and emtricitabine) in male and female adult HIV type 1 infected patients
Item
To construct a treatment option with Viramune (nevirapine) and antiretroviral, e.g. Combivir (fixed dose combination of Zidovudine and Lamivudine), Kivexa (fixed dose combination of Abacavir and Lamivudine) or Truvada (fixed dose combination of tenofovir and emtricitabine) in male and female adult HIV type 1 infected patients
boolean
C0039798 (UMLS CUI 2011AA)
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
C0599685 (UMLS CUI 2011AA)
C0717880 (UMLS CUI 2011AA)
324859007 (SNOMED CT 2011_0131)
C1567988 (UMLS CUI 2011AA)
C0663655 (UMLS CUI 2011AA)
116084008 (SNOMED CT 2011_0131)
MTHU013841 (LOINC Version 232)
C0209738 (UMLS CUI 2011AA)
386897000 (SNOMED CT 2011_0131)
MTHU013847 (LOINC Version 232)
C1528494 (UMLS CUI 2011AA)
C0384228 (UMLS CUI 2011AA)
422091007 (SNOMED CT 2011_0131)
MTHU015506 (LOINC Version 232)
C0909839 (UMLS CUI 2011AA)
404856006 (SNOMED CT 2011_0131)
MTHU018643 (LOINC Version 232)
C0086582 (UMLS CUI 2011AA)
248153007 (SNOMED CT 2011_0131)
M (HL7 V3 2006_05)
C0086287 (UMLS CUI 2011AA)
248152002 (SNOMED CT 2011_0131)
F (HL7 V3 2006_05)
C2363741 (UMLS CUI 2011AA)
10068341 (MedDRA 14.1)
C0011900 (UMLS CUI 2011AA)
439401001 (SNOMED CT 2011_0131)
MTHU008876 (LOINC Version 232)
HIV type 1 infected patients, who have either not been treated previously
Item
HIV type 1 infected patients, who have either not been treated previously
boolean
C2363741 (UMLS CUI 2011AA)
10068341 (MedDRA 14.1)
C1518422 (UMLS CUI 2011AA)
C1514463 (UMLS CUI 2011AA)
HIV type 1 infected patients, whose previous combination treatment with protease inhibitors has failed
Item
HIV type 1 infected patients, whose previous combination treatment with protease inhibitors has failed
boolean
C2363741 (UMLS CUI 2011AA)
10068341 (MedDRA 14.1)
C0205156 (UMLS CUI 2011AA)
9130008 (SNOMED CT 2011_0131)
C0556895 (UMLS CUI 2011AA)
229554006 (SNOMED CT 2011_0131)
C0033607 (UMLS CUI 2011AA)
412127001 (SNOMED CT 2011_0131)
C0231175 (UMLS CUI 2011AA)
HIV type 1 infected patients, who have to switch their previous treatment from protease inhibitor or nucleosidaI reverse transcriptase inhibitor due to side effects or intolerability after achieving suppression of viral load below the limit of detection.
Item
HIV type 1 infected patients, who have to switch their previous treatment from protease inhibitor or nucleosidaI reverse transcriptase inhibitor due to side effects or intolerability after achieving suppression of viral load below the limit of detection.
boolean
C2363741 (UMLS CUI 2011AA)
10068341 (MedDRA 14.1)
C0392747 (UMLS CUI 2011AA)
243326001 (SNOMED CT 2011_0131)
C0039798 (UMLS CUI 2011AA)
C0033607 (UMLS CUI 2011AA)
412127001 (SNOMED CT 2011_0131)
C1373111 (UMLS CUI 2011AA)
C0879626 (UMLS CUI 2011AA)
281647001 (SNOMED CT 2011_0131)
10067484 (MedDRA 14.1)
CL415164 (UMLS CUI 2011AA)
OINT (HL7 V3 2006_05)
C0877596 (UMLS CUI 2011AA)
10049835 (MedDRA 14.1)
Viramune (nevirapine) is indicated as part of combination therapy for the antiviral treatment of HIV-1 infected patients with advanced or progressive immunodeficiency.
Item
Viramune (nevirapine) is indicated as part of combination therapy for the antiviral treatment of HIV-1 infected patients with advanced or progressive immunodeficiency.
boolean
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
C1444656 (UMLS CUI 2011AA)
410535002 (SNOMED CT 2011_0131)
C0556895 (UMLS CUI 2011AA)
229554006 (SNOMED CT 2011_0131)
C2363964 (UMLS CUI 2011AA)
10068724 (MedDRA 14.1)
C2363741 (UMLS CUI 2011AA)
10068341 (MedDRA 14.1)
Item Group
Ausschlusskriterien
CL425201 (UMLS CUI 2011AA)
Age < 18 years
Item
Alter unter 18 Jahre
boolean
C0001779 (UMLS CUI 2011AA)
397669002 (SNOMED CT 2011_0131)
Pregnant female patients
Item
Pregnant female patients
boolean
C0549206 (UMLS CUI 2011AA)
Hypersensitivity to the active substance or to any of the excipients of Viramune (nevirapine) or antiretroviral in combination with Viramune, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine).
Item
Hypersensitivity to the active substance or to any of the excipients of Viramune (nevirapine) or antiretroviral in combination with Viramune, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir and emtricitabine).
boolean
C0020517 (UMLS CUI 2011AA)
418634005 (SNOMED CT 2011_0131)
T78.40 (ICD-10-CM Version 2010)
C0205177 (UMLS CUI 2011AA)
55561003 (SNOMED CT 2011_0131)
C0439861 (UMLS CUI 2011AA)
105590001 (SNOMED CT 2011_0131)
C0015237 (UMLS CUI 2011AA)
360215002 (SNOMED CT 2011_0131)
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
C0599685 (UMLS CUI 2011AA)
C1947911 (UMLS CUI 2011AA)
C0717880 (UMLS CUI 2011AA)
324859007 (SNOMED CT 2011_0131)
C1567988 (UMLS CUI 2011AA)
C0663655 (UMLS CUI 2011AA)
116084008 (SNOMED CT 2011_0131)
MTHU013841 (LOINC Version 232)
C0209738 (UMLS CUI 2011AA)
386897000 (SNOMED CT 2011_0131)
MTHU013847 (LOINC Version 232)
C1528494 (UMLS CUI 2011AA)
C0384228 (UMLS CUI 2011AA)
422091007 (SNOMED CT 2011_0131)
MTHU015506 (LOINC Version 232)
C0909839 (UMLS CUI 2011AA)
404856006 (SNOMED CT 2011_0131)
MTHU018643 (LOINC Version 232)
Viramune (nevirapine) should not be readministered to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine.
Item
Viramune (nevirapine) should not be readministered to patients who have required permanent discontinuation for severe rash, rash accompanied by constitutional symptoms, hypersensitivity reactions, or clinical hepatitis due to nevirapine.
boolean
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
C1518422 (UMLS CUI 2011AA)
C0376495 (UMLS CUI 2011AA)
C0205082 (UMLS CUI 2011AA)
24484000 (SNOMED CT 2011_0131)
C0015230 (UMLS CUI 2011AA)
112625008 (SNOMED CT 2011_0131)
10037844 (MedDRA 14.1)
MTHU015064 (LOINC Version 232)
R21 (ICD-10-CM Version 2010)
782.1 (ICD-9-CM Version 2011)
C0009812 (UMLS CUI 2011AA)
MTHU034799 (LOINC Version 232)
C0020517 (UMLS CUI 2011AA)
418634005 (SNOMED CT 2011_0131)
T78.40 (ICD-10-CM Version 2010)
C0019158 (UMLS CUI 2011AA)
29001004 (SNOMED CT 2011_0131)
10019717 (MedDRA 14.1)
CL420107 (UMLS CUI 2011AA)
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
Viramune (nevirapine) should not be used in patients with severe hepatic impairment (Child-Pugh C) or pre-treatment GOT (Glutamic Oxaloacetic Transaminase) or GPT (Glutamic Pyruvate Transaminase) > 5 upper limit of normal until baseline GOT/GPT are stabilised < 5 upper limit of normal.
Item
Viramune (nevirapine) should not be used in patients with severe hepatic impairment (Child-Pugh C) or pre-treatment GOT (Glutamic Oxaloacetic Transaminase) or GPT (Glutamic Pyruvate Transaminase) > 5 upper limit of normal until baseline GOT/GPT are stabilised < 5 upper limit of normal.
boolean
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
C1518422 (UMLS CUI 2011AA)
C1524063 (UMLS CUI 2011AA)
260676000 (SNOMED CT 2011_0131)
C0948807 (UMLS CUI 2011AA)
10052254 (MedDRA 14.1)
C4050412 (UMLS CUI 2011AA)
C0439106 (UMLS CUI 2011AA)
257962003 (SNOMED CT 2011_0131)
C1514463 (UMLS CUI 2011AA)
C0004002 (UMLS CUI 2011AA)
26091008 (SNOMED CT 2011_0131)
MTHU004883 (LOINC Version 232)
C0001899 (UMLS CUI 2011AA)
56935002 (SNOMED CT 2011_0131)
MTHU006766 (LOINC Version 232)
C1519815 (UMLS CUI 2011AA)
Viramune (nevirapine) should not be readministered in patients who previously had GOT or GPT (Liver enzymes) > 5 ULN (upper limit of normal) during Viramune (nevirapine) therapy and had recurrence of liver function abnormalities upon readministration of Viramune (nevirapine)
Item
Viramune (nevirapine) should not be readministered in patients who previously had GOT or GPT (Liver enzymes) > 5 ULN (upper limit of normal) during Viramune (nevirapine) therapy and had recurrence of liver function abnormalities upon readministration of Viramune (nevirapine)
boolean
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
C1518422 (UMLS CUI 2011AA)
C0376495 (UMLS CUI 2011AA)
C0205156 (UMLS CUI 2011AA)
9130008 (SNOMED CT 2011_0131)
C0004002 (UMLS CUI 2011AA)
26091008 (SNOMED CT 2011_0131)
MTHU004883 (LOINC Version 232)
C0001899 (UMLS CUI 2011AA)
56935002 (SNOMED CT 2011_0131)
MTHU006766 (LOINC Version 232)
C0857093 (UMLS CUI 2011AA)
10014480 (MedDRA 14.1)
C0347984 (UMLS CUI 2011AA)
371881003 (SNOMED CT 2011_0131)
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
C0039798 (UMLS CUI 2011AA)
CL429630 (UMLS CUI 2011AA)
C0086565 (UMLS CUI 2011AA)
75183008 (SNOMED CT 2011_0131)
10019670 (MedDRA 14.1)
Herbal preparations containing St Johns wort (Hypericum perforatum) must not be used while taking Viramune (nevirapine) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine
Item
Herbal preparations containing St Johns wort (Hypericum perforatum) must not be used while taking Viramune (nevirapine) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine
boolean
C0949854 (UMLS CUI 2011AA)
C0936242 (UMLS CUI 2011AA)
51621002 (SNOMED CT 2011_0131)
C1518422 (UMLS CUI 2011AA)
C1524063 (UMLS CUI 2011AA)
260676000 (SNOMED CT 2011_0131)
C0347984 (UMLS CUI 2011AA)
371881003 (SNOMED CT 2011_0131)
C1512806 (UMLS CUI 2011AA)
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
C0035647 (UMLS CUI 2011AA)
30207005 (SNOMED CT 2011_0131)
RSK (HL7 V3 2006_05)
C0205216 (UMLS CUI 2011AA)
1250004 (SNOMED CT 2011_0131)
D (HL7 V3 2006_05)
C0683150 (UMLS CUI 2011AA)
C0392756 (UMLS CUI 2011AA)
260400001 (SNOMED CT 2011_0131)
C1280500 (UMLS CUI 2011AA)
253861007 (SNOMED CT 2011_0131)
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
The available pharmacokinetic data suggest that the concomitant use of rifampicin and Viramune (nevirapine) is not recommended.
Item
The available pharmacokinetic data suggest that the concomitant use of rifampicin and Viramune (nevirapine) is not recommended.
boolean
C0031328 (UMLS CUI 2011AA)
C1511726 (UMLS CUI 2011AA)
C0038659 (UMLS CUI 2011AA)
C1518422 (UMLS CUI 2011AA)
C0034866 (UMLS CUI 2011AA)
MTHU036724 (LOINC Version 232)
RMD (HL7 V3 2006_05)
CL415222 (UMLS CUI 2011AA)
C1524063 (UMLS CUI 2011AA)
260676000 (SNOMED CT 2011_0131)
C0035608 (UMLS CUI 2011AA)
387159009 (SNOMED CT 2011_0131)
MTHU008474 (LOINC Version 232)
C0132326 (UMLS CUI 2011AA)
386898005 (SNOMED CT 2011_0131)
MTHU013861 (LOINC Version 232)
Zum Seitenanfang zurückkehren 

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video